Prostate cancer has become a major public health burden worldwide. Castration or hormonal therapy is the mainstay of treatment for the management of advanced prostate cancer. Initially patients respond to the primary hormonal treatment or androgen deprivation therapy and eventually after 1 to 2 years patient becomes resistant to it, this is termed as castrate resistant prostate cancer (CRPC). This slide set explains the concept of CRPC, mechanisms of development of CRPC and management of CRPC focusing on abiraterone acetate. This slide set also mentions about mechanism of action of abiraterone acetate, the available clinical evidence on the drug and precautions to be advocated while prescribing it in patients with metastatic CRPC.